Jefferies Group LLC Denali Therapeutics Inc. Transaction History

Jefferies Group LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$50.3 - $78.44 $1.06 Million - $1.66 Million	-21,100 Closed	0 $0
Q1 2021 Sep 21, 2023	SELL	$53.8 - $81.53 $478,820 - $725,617	-8,900 Reduced 29.67%	21,100 $1.2 Million
Q1 2021 May 14, 2021	SELL	$53.8 - $81.53 $478,820 - $725,617	-8,900 Reduced 29.67%	21,100 $1.21 Million
Q4 2020 Sep 21, 2023	BUY	$36.89 - $93.56 $1.11 Million - $2.81 Million	30,000 New	30,000 $2.51 Million
Q4 2020 Feb 16, 2021	BUY	$36.89 - $93.56 $1.11 Million - $2.81 Million	30,000 New	30,000 $2.51 Million
Q4 2019 Feb 13, 2020	SELL	$14.4 - $19.99 $247,219 - $343,188	-17,168 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$15.32 - $21.92 $263,013 - $376,322	17,168 New	17,168 $263,000

241

111M

80K

36.8K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $1.71B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.